Closing the gap...next steps in optimizing therapy.
D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003967:Diarrhea / Q000150:complications; D004304:Dosage Forms; D016503:Drug Delivery Systems; D004345:Drug Industry; D004359:Drug Therapy, Combination; D006678:HIV / Q000235:genetics; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D019247:HIV Wasting Syndrome / Q000150:complications; D006801:Humans; D008119:Lobbying; D009154:Mutation; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use; D019562:Viral Load; D014839:Vomiting / Q000150:complications
D019380:Anti-HIV Agents; D004304:Dosage Forms; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors